Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Systemic mastocytosis with associated hematological neoplasm (SM-AHN) poses diagnostic challenges because of the coexistence of atypical mast cell proliferation and hematological neoplasms. We assessed the presence of SM-AHN in patients with acute myeloid leukemia (AML) with RUNX1::RUNX1T1 from 2014 to 2020. Bone marrow (BM) samples were evaluated for mast cell aggregates using CD117 and CD25 immunohistochemical (IHC) staining. The KIT D816V variant burden at diagnosis and post induction was assessed using droplet digital PCR. Among 23 patients diagnosed as having AML with RUNX1::RUNX1T1, four (17.4%) were also diagnosed as having SM-AHN. No significant differences in clinical characteristics or overall survival (P=0.565) were observed between patients with or without SM-AHN, except for the presence of KIT variants (P=0.040). After induction therapy, IHC staining revealed the presence of mast cell aggregates in the BM, and the KIT D816V variant burden decreased with decreasing blast count and was similar in BM aspirates, smear slides, and sections. Concomitant SM-AHN was not infrequent in AML patients with RUNX1::RUNX1T1. This study showed the importance of CD117 and CD25 IHC staining after induction chemotherapy for SM-AHN screening, especially in patients with KIT variants.
Abstract
Systemic mastocytosis with associated hematological neoplasm (SM-AHN) poses diagnostic challenges because of the coexistence of atypical mast cell proliferation and hematological neoplasms. We assessed the presence of SM-AHN in patients with acute myeloid leukemia (AML) with RUNX1::RUNX1T1 from 2014 to 2020. Bone marrow (BM) samples were evaluated for mast cell aggregates using CD117 and CD25 immunohistochemical (IHC) staining. The KIT D816V variant burden at diagnosis and post induction was assessed using droplet digital PCR. Among 23 patients diagnosed as having AML with RUNX1::RUNX1T1, four (17.4%) were also diagnosed as having SM-AHN. No significant differences in clinical characteristics or overall survival (P=0.565) were observed between patients with or without SM-AHN, except for the presence of KIT variants (P=0.040). After induction therapy, IHC staining revealed the presence of mast cell aggregates in the BM, and the KIT D816V variant burden decreased with decreasing blast count and was similar in BM aspirates, smear slides, and sections. Concomitant SM-AHN was not infrequent in AML patients with RUNX1::RUNX1T1. This study showed the importance of CD117 and CD25 IHC staining after induction chemotherapy for SM-AHN screening, especially in patients with KIT variants.
참고문헌 (20)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" (2017), IARC Press
- Pullarkat ST, "Systemic mastocytosis associated with t(8;21)(q22;q22)acute myeloid leukemia", J Hematop, 2, pp.27~33 (2009)
- Horny HP, "Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases : a histopathological challenge", J Clin Pathol, 57, pp.604~608 (2004)
- Johnson RC, "Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22)", Am J Clin Pathol, 140, pp.525~535 (2013)
- Sotlar K, "CD25 indicates the neoplastic phenotype of mast cells : a novel immunohistochemical marker for the diagnosis of systemic mastocytosis(SM)in routinely processed bone marrow biopsy specimens", Am J Surg Pathol, 28, pp.1319~1325 (2004)
- Reiter A, "New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis", Blood, 135, pp.1365~1376 (2020)
- Döhner H, "Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel", Blood, 129, pp.424~447 (2017)
- Yabe M, "Systemic mastocytosis associated with t(8;21)acute myeloid leukemia in a child : detection of the D816A variant of KIT", Pediatr Blood Cancer, 59, pp.1313~1316 (2012)
- Craig JW, "Detection of the KITD816V variant in myelodysplastic and", or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis, 2020, pp.33, 1135~1145
- Pullarkat V, "Neoplastic mast cells in systemic mastocytosis associated with t(8;21)acute myeloid leukemia are derived from the leukemic clone", Leuk Res, 31, pp.261~265 (2007)
- Greiner G, "Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis", Haematologica, 105, pp.366~374 (2020)
- Nagai S, "The origin of neoplastic mast cells in systemic mastocytosis with AML1", ETO-positive acute myeloid leukemia, 2007, pp.35, 1747~1752
- Escribano L, "Systemic mastocytosis associated with acute myeloid leukemia : case report and implications for disease pathogenesis", J Allergy Clin Immunol, 114, pp.28~33 (2004)
- Al Hinai ASA, "Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia", Leukemia, 34, pp.2220~2224 (2020)
- Arock M, "KIT mutation analysis in mast cell neoplasms : recommendations of the European Competence Network on Mastocytosis", Leukemia, 29, pp.1223~1232 (2015)
- Laine E, "Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region : implications for dimerization and activation mechanisms", PLoS Comput Biol, 7, pp.e1002068~ (2011)
- Gotlib J, "Efficacy and safety of midostaurin in advanced systemic mastocytosis", N Engl J Med, 374, pp.2530~2541 (2016)
- Grootens J, "Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis", EBioMedicine, 43, pp.150~158 (2019)
- Gotlib J, "Efficacy and safety of avapritinib in advanced systemic mastocytosis : interim analysis of the phase 2 PATHFINDER trial", Nat Med, 27, pp.2192~2199 (2021)
- Kristensen T, "Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia", Leuk Lymphoma, 53, pp.1338~1344 (2012)